ReviewOncology research2026
Metastatic Triple Negative Breast Cancer: Navigating a Rapidly Evolving Therapeutic Landscape.
Review in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple negative breast cancer (TNBC) is defined by the absence of oestrogen receptor, progesterone receptor, and HER2 expression, and carries a disproportionate burden of breast cancer-related mortality due to its aggressive biology and historically limited therapeutic options. The treatment landscape of metastatic TNBC has undergone a fundamental transformation over the past decade, driven by immune checkpoint inhibitors, antibody-drug conjugates (ADCs), and the identification of actionable genomic alterations. This review provides a comprehensive, clinically oriented appraisal of the current and emerging therapeutic landscape of metastatic TNBC, encompassing its molecular underpinnings and tumour microenvironment biology. We critically evaluate the evolving roles of immune checkpoint inhibition, ADCs, PARP inhibitors, and novel targeted approaches, discuss mechanisms of resistance and biomarker limitations, and propose a framework for rational, biomarker-guided treatment selection and sequencing to support evidence-based clinical decision-making in this rapidly evolving field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.